Kairos Pharma (NYSEAMERICAN:KAPA) Given “Buy” Rating at D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $9.00 target price on the stock.

Kairos Pharma Stock Performance

Shares of NYSEAMERICAN KAPA traded up $0.06 during trading on Thursday, hitting $1.00. The company had a trading volume of 335,304 shares, compared to its average volume of 2,693,338. Kairos Pharma has a 52 week low of $0.85 and a 52 week high of $4.00. The firm has a 50-day moving average of $1.36.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.